I am a Consultant Respiratory Physician at the Royal Brompton and Harefield NHS Foundation Trust and Horonary Clinical Senior Lecturer at Imperial College London.
Following completion of my medical training at Imperial College London alongside an intercalated BSc, I trained as a respiratory doctor within North West London and spent time working within the lung transplant unit at Harefield Hospital and the Host Defence Unit at the Royal Brompton hospital. It was during this time that I encountered numerous individuals with fungal lung infection and developed my academic interest to try and better understand host susceptibility to fungal infection and develop translational research strategies to improve outcome.
This interest led to a MRC clinical PhD research fellowship in 2012-2015 in the Armstrong-James laboratory at Imperial College London analysing the effects of calcineurin inhibition on the human macrophage response to Aspergillus fumigatus using a combination of high-resolution time-lapse confocal microscopy alongside an 'omics' based approach. This work was published in the American Journal of Critical Care Medicine and presented at numerous national and international presentations.
Following completion of my PhD and clinical training, I took up a Consultant position at the Royal Brompton and Harefield NHS Foundation Trust in October 2016, working in the adult Cystic Fibrosis and Host Defence departments. I have continued and expanded my academic interests and research during this time, receiving numerous research awards and funding.
- MRC Clinical Academic Research Partnership award - 2019
- CF Trust Venture Innovation award - 2019
- Vertex Research Innovation award - 2018
- Gilead Invasive Fungal Infection fellowship award - 2018
- CF Trust Clinical Excellance and Innovation award - 2017
- Darzi Fellowship in Clinical Leadership (Sponsor) - 2017 and 2018
- MRC Clinical PhD Research Fellowship - 2012
Fungal Resistance Evolution and Acquisition in chronic Lung disease (FREAL) study. Primary Investigator in MRC funded multicentre prospective longitudinal study using whole genome sequencing to understand fungal resistance evolution and acquisition in chronic lung disease and validating a novel point-of-care loop-mediated isothermal amplification (LAMP)-based detection assay of Aspergillus fumigatus resistance. Collaborators - Professor Matthew Fisher, Dr Pantelis Georgiou, Dr Darius Armstrong-James, Imperial College London and Professor James Chalmers, University Of Dundee.
TrIFIC: Targeting Immunotherapy for Fungal Infections in Cystic Fibrosis. Co-Investigator in CF Trust Strategic Research Centre grant to immunophenotype fungal disease in Cystic Fibrosis and assess targeted immunotherapeutics to improve outcome in CF fungal disease.
Using an iPSC-derived macrophage model of Aspergillus fumigatus infection to determine CFTR-dependent effects on fungal killing. Primary investigator in collaborative research programme developing iPSC-derived macrophage models of pulmonary fungal infection.
Use of minimally supervised machine learning to analyse computed tomography imaging of chronic pulmonary fungal disease. Co-Investigator with Dr Elsa Angelini, Imperial College London.
Tablet and web-based audiometry as screening tools to detect hearing loss in adults with Cystic Fibrosis. Lead investigator in prospective multicentre cross-sectional study. Academic Collaborators - Dr Lorenzo Picinali, Dr Melody Zhifang Ni, Dr Deborah Morris-Rosendahl, Imperial College London.
Thee S, Ekkelenkamp M, Shah A, 2023, AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease., Eur Respir J, Vol:62
et al., 2023, The effect of inhaled corticosteroids on pneumonia risk in patients with COPD-bronchiectasis overlap: a UK population-based case-control study, Chest, Vol:164, ISSN:0012-3692, Pages:875-884
RECOVERY Collaborative Group, 2023, Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet, Vol:401, ISSN:0140-6736, Pages:1499-1507
et al., 2023, COVID-19 associated pulmonary aspergillosis in patients on extracorporeal membrane oxygenation treatment-a retrospective study, Journal of Fungi, Vol:9, ISSN:2309-608X
et al., 2023, Breaking the mould, a first parse at natural language processing in aspergillosis diagnosis, Journal of Thoracic Disease, Vol:15, ISSN:2072-1439, Pages:17-21